A 1 Month Randomized Placebo Controlled, Double Blind Trial With a 5 Month Open Extension Phase to Explore the Efficacy of Zonisamide on Apnea/Hypopnea Index in Overweight/Obese Sleep Apnea Patients.
Phase of Trial: Phase II
Latest Information Update: 22 Apr 2014
At a glance
- Drugs Zonisamide (Primary)
- Indications Obesity; Sleep apnoea syndrome
- Focus Therapeutic Use
- 11 Nov 2013 Status changed from active, no longer recruiting to completed.
- 10 Sep 2013 Results presented at the 23rd Annual Congress of the European Respiratory Society.
- 24 Jan 2013 New trial record